Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Read More
We exist to help people of all ages, from day one and every day after.
Learn more about our FDA-approved medicine for pediatric patients with relapsed or refractory pediatric low-grade glioma (pLGG).
By sharing this Framework, we hope to prompt further discussions and greater collaboration to advance pediatric cancer research and drug development. It is one step in the right direction. We look forward to building upon our learnings, evolving the Framework, and working together to change the outlook for children with cancer and their families.
Download printer-friendly version
Or request a printed copy (or copies) of the whitepaper booklet
